MORE►
Colossal Biosciences
Colossal leadership team, L to R: Peter Phillips, chief business officer; Andrew Busey, chief product officer; Sarah Grant, chief of staff; Ben Lamm, co-founder/CEO; George Church, PhD, co-founder; Eriona Hysolli, head of biological sciences; Kent Wakeford, COO; and Brian Beard, chief legal officer. [Photo credit: John Davidson Photography]
Mammoth Project: Dallas’ Colossal Raises $60M to Advance Genetic Engineering and ‘De-Extinction’ Technologies
by Quincy Preston and David Seeley | Mar 9, 2022
Colossal launched last September with a plan to "de-extinct" the woolly mammoth by using CRISPR genetic engineering to create a mammoth-elephant hybrid.
With a total raise of $75 million to date, the startup aims to
have its first set of mammoth-elephant hybrid calves "in 4 to 6 years," co-founder and CEO Ben Lamm told us. But Colossal's goals extend much further—with the potential "to advance human health, enhance food production, reduce environmental impact, and optimize animal health and welfare."
by David Seeley |
Sep 13, 2021
It's not "Jurassic Park," but it's almost as amazing. Hypergiant founder Ben Lamm is launching a new biosciences and genetics startup—Colossal—with $15 million in private funding. The goal: Use genomics to "de-extinct" the woolly mammoth and re-wild it on the Arctic tundra. Lamm's co-founder, Harvard geneticist Dr. George Church, says this "grand vision" could lead to big opportunities in conservation, biodiversity, carbon sequestration, and more.
MORE►
